Please assess the completion status of the following clinical trial:

Trial Title: Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective cardiac surgery (valve surgery and/or CABG)~* 18 years and above~* Mentally competent~Exclusion Criteria:~* History of atrial fibrillation (AF) or atrial flutter.~* Concomitant rhythm associated procedures (MAZE (surgical ablation)/PVI (pulmonary vein isolation)).~* Pre-existing severe renal impairment (eGFR\<30 ml/min).~* Pre-existing 3rd degree heart block without pacemaker presence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnesium Sulfate (Type: ACTIVE_COMPARATOR): Magnesium sulfate is the active compound and will be administered to achieve plasma serum level of magnesium between 1.5 and 2.0 mmol/L according to the study protocol.
- Ringers Lactate (Type: PLACEBO_COMPARATOR): Ringers Lactate is the comparator/placebo and will be administered according to the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).